Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
“Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh will be responsible for legal and compliance matters and will become part of the management team of Immunic,” reports Immunic, Inc in their blog.
“Inderpal is a seasoned legal executive, having spent 20 years in-house, advising several of the world’s largest life sciences companies. As such, he brings to Immunic extensive legal knowledge related to clinical development, operations, regulatory affairs, and commercialization,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. “We welcome Inderpal to the management team and look forward to his guidance as we continue to advance our pipeline of selective oral immunology therapies, including our lead program, IMU-838, through clinical development and eventually to potential regulatory approval.”
